巨噬细胞迁移抑制因子在多发性骨髓瘤中的研究进展  

Research progress of macrophage migration inhibitory factor in multiple myeloma

作　　者：姚金融 周竟心 胡娜[1] 陈伟 高玲 Yao Jinrong;Zhou Jingxin;Hu Na;Chen Wei;Gao Ling(Department of Hematology,Affiliated Suqian First People′s Hospital of Nanjing Medical University,Suqian 223800,Jiangsu Province,China;Department of Hematology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221132,Jiangsu Province,China)

机构地区：[1]南京医科大学附属宿迁第一人民医院血液科,宿迁223800 [2]徐州医科大学附属医院血液科,徐州221132

出　　处：《国际输血及血液学杂志》2024年第6期545-549,共5页International Journal of Blood Transfusion and Hematology

基　　金：宿迁市科技计划项目(SY202218);宿迁市科技项目(K202309)。

摘　　要：巨噬细胞迁移抑制因子(MIF)是趋化因子样炎症细胞因子,广泛分布于多种细胞,通过与CXC基序趋化因子受体(CXCR)4和CD74结合降低肿瘤细胞对骨髓基质的黏附,促进肿瘤细胞的增殖。多发性骨髓瘤(MM)细胞MIF表达上调是导致MM患者对蛋白酶体抑制剂(PI)耐药的重要原因,MIF为MM的潜在治疗靶点之一。笔者拟就MIF诱导的MM细胞免疫微环境的改变及耐药机制的研究进展进行综述,旨在为MM患者的治疗提供新的视角和可能的治疗策略。Macrophage migration inhibitory factor(MIF)is a chemokine-like inflammatory cytokine widely distributed in a variety of cells.MIF can inhibit adhesion of tumor cells to bone marrow matrix and promote the proliferation of tumor cells by binding to CXC motif chemokine receptor(CXCR)4 and CD74.Up-regulation of MIF expression in multiple myeloma(MM)cells is an important cause of MM patients′resistance to proteasome inhibitors(PI),and MIF is a potential therapeutic target for MM.This article reviews research progress of MIF-induced changes in cellular immune microenvironment and drug resistance mechanisms in MM,in order to provide a new perspective and possible therapeutic strategies for the treatment of patients with MM.

关 键 词：多发性骨髓瘤 细胞微环境 预后 抗药性 肿瘤 蛋白酶体抑制剂 分子靶向治疗 巨噬细胞迁延抑制因子 

分 类 号：R733.3[医药卫生—肿瘤]